Graig C. Suvannavejh

In a report published Wednesday, MLV & Co. analyst Graig C. Suvannavejh reiterated a Buy rating on TG Therapeutics (NASDAQ: TGTX), and raised the price target from $10.00 to $16.00. In the report, MLV & Co noted, “We now raise our PT on TGTX to $16 (vs. our prior $10) on: 1) flawless...

In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh downgraded the rating on MannKind Corporation (NASDAQ: MNKD) from Buy to Hold, but raised the price target from $10.00 to $11.00. In the report, MLV & Co noted, “Capping a long journey, FDA has now approved Afrezza, MNKD's...

In a report published Monday, MLV & Co analyst Graig C. Suvannavejh reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX), but lowered the price target from $27.00 to $21.00. In the report, MLV & Co noted, “KERX reported 1Q results last week, but the main focus was mgmt's...

In a report published Monday, MLV & Co analyst Graig C. Suvannavejh initiated coverage on pSivida Corp. (NASDAQ: PSDV) with a Buy rating and $6.00 price target. In the report, MLV & Co noted, “We're attending ARVO (the annual mtg for retinal specialists), and live from Orlando, we initiate...

In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh upgraded the rating on XOMA (NASDAQ: XOMA) from Hold to Buy, and reiterated the $7.00 price target. In the report, MLV & Co noted, “We now upgrade shares of XOMA. Our call is based on 1) valuation and 2) optimism around...

In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh downgraded the rating on Prana Biotechnology Limited (NASDAQ: PRAN) from Buy to Hold, and lowered the price target from $11.00 to $3.00. In the report, MLV & Co noted, “In yet another setback to the Alzheimer's disease (...

In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh downgraded the rating on XOMA Corp. (NASDAQ: XOMA) from Buy to Hold, and lowered the price target from $8.00 to $7.00. In the report, MLV & Co noted, “Following 1) negative P2 data for gevokizumab (gevo) last week in...

In a report published Thursday, MLV & Co analyst Graig C. Suvannavejh reiterated a Buy rating on Ligand Pharmaceuticals (NASDAQ: LGND), and raised the price target from $82.00 to $96.00. In the report, MLV & Co noted, “Yesterday, LGND reported a strong 4Q, beating recently raised guidance...